\ud83d\udd2cRESEARCH AND DEVELOPMENT (R&D) has always been a key factor in the pharmaceutical industry \u269b\ufe0f<\/p>\n\n\n\n
\ud83c\udf0dHowever, with the arrival of the Covid-19 pandemic, the need to invest even more in this area of the production process became evident. This trend is evident in IQVIA’s latest report, “Global Trends in R&D 2023,” which analyzes numerous activities related to the industry, such as approvals and launches of NEW DRUGS, GENERAL RESEARCH ACTIVITY, AND THE NUMBER OF CLINICAL TRIALS INITIATED. The report also assesses the state of R&D financing and the activity of companies that make up the sector.<\/p>\n\n\n\n
\ud83d\udcb8Overall, the report shows that pharmaceutical companies have increased their investment in R&D by 43% in the last five years. Of the \u20ac666.5 billion in revenue generated by the top pharmaceutical companies in 2022, the report states that 18.8% OF THE TOTAL REVENUE WAS ALLOCATED TO DEVELOPMENT PROJECTS, which translates to ONE IN EVERY FIVE euros generated.<\/p>\n\n\n\n
\ud83d\udc8aDespite this positive trend and the fact that 2022 saw the highest R&D investment in history, the percentage of revenue dedicated to R&D has fallen to 19%, four tenths lower than in 2021 when the index was at 19.3%. According to IQVIA, this decrease is due to FEWER CLINICAL TRIALS THAT FAILED \ud83d\udc4d\ud83c\udffb, which means they did not have to repeat or cancel them.<\/p>\n\n\n\n
\ud83e\udd13 It’s great to see the pharmaceutical industry’s continued investment in R&D, particularly during these challenging times. This investment is essential for the development of new and INNOVATIVE MEDICINES TO address unmet medical needs. Let’s hope that this trend continues and that the industry continues to prioritize R&D investment in the years to come.<\/p>\n","protected":false},"excerpt":{"rendered":"
\ud83d\udd2cRESEARCH AND DEVELOPMENT (R&D) has always been a key factor in the pharmaceutical industry \u269b\ufe0f \ud83c\udf0dHowever, with the arrival of the Covid-19 pandemic, the need to invest even more in this area of the production process became evident. This trend is evident in IQVIA’s latest report, “Global Trends in R&D 2023,” which analyzes numerous activities related to the industry, such as approvals and launches of NEW DRUGS, GENERAL RESEARCH ACTIVITY, AND THE NUMBER OF CLINICAL TRIALS INITIATED. The report also assesses the state of R&D financing and the activity of companies that make up the sector. \ud83d\udcb8Overall, the report shows that pharmaceutical companies have increased their investment in R&D by 43% in the last five years. Of the \u20ac666.5 billion in revenue generated by the top pharmaceutical companies in 2022, the report states that 18.8% OF THE TOTAL REVENUE WAS ALLOCATED TO DEVELOPMENT PROJECTS, which translates to ONE IN EVERY FIVE euros generated. \ud83d\udc8aDespite this positive trend and the fact that 2022 saw the highest R&D investment in history, the percentage of revenue dedicated to R&D has fallen to 19%, four tenths lower than in 2021 when the index was at 19.3%. According to IQVIA, this decrease is due to FEWER CLINICAL TRIALS THAT FAILED \ud83d\udc4d\ud83c\udffb, which means they did not have to repeat or cancel them. \ud83e\udd13 It’s great to see the pharmaceutical industry’s continued investment in R&D, particularly during these challenging times. This investment is essential for the development of new and INNOVATIVE MEDICINES TO address unmet medical needs. Let’s hope that this trend continues and that the industry continues to prioritize R&D investment in the years to come.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6,8],"tags":[],"class_list":["post-325","post","type-post","status-publish","format-standard","hentry","category-corporate-business","category-healthcare"],"_links":{"self":[{"href":"https:\/\/rafaguilarc.com\/index.php?rest_route=\/wp\/v2\/posts\/325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rafaguilarc.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rafaguilarc.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rafaguilarc.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rafaguilarc.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=325"}],"version-history":[{"count":0,"href":"https:\/\/rafaguilarc.com\/index.php?rest_route=\/wp\/v2\/posts\/325\/revisions"}],"wp:attachment":[{"href":"https:\/\/rafaguilarc.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rafaguilarc.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rafaguilarc.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}